Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 21, 2006

Genomatica Partners with Diversa on Improved Enzyme Production

  • Genomatica will collaborate with Diversa to use Genomatica’s technologies to develop more efficient biomanufacturing processes for biologically-derived enzyme products. Genomatica will focus on obtaining productivity and yield targets to improve manufacturing efficiency and costs.

    Genomatica will receive research support, commercial milestone payments, and will be eligible for royalty payments based on future product sales.

    “The marketplace continues to value the growing strengths of our proprietary Integrated Metabolic Engineering Platform to design and engineer high performance microbial factories that are optimized to produce high-value bioproducts,” says Christophe Schilling, president and CSO at Genomatica. “We look forward to leveraging both companies' combined expertise in this field to achieve increased success in the commercialization of Diversa products.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »